BioTech Drug Development healthcare technology 
Digital Health Global
APRIL 25, 2024
About Koneksa Koneksa is a healthcare technology company pioneering evidence-based digital biomarkers to accelerate clinical research and guide decision-making in drug development and market strategy. These adverse events often lead to hospitalizations and treatment interruptions that can reduce treatment efficacy.
Digital Health Global
MARCH 2, 2023
As part of the partnership, SSI will expand Koneksa’s medical strategy division, especially in translational and clinical drug development. Koneksa clients gain access to a team of PhDs and MDs at SSI with expertise in drug development.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Digital Health Global
JUNE 13, 2023
The utilization of evidence-based digital biomarkers is the key to transforming healthcare,” said Chris Benko, CEO, Koneksa. “We’re We’re on a mission to revolutionize drug development in clinical trials by harnessing the power of our digital solutions with real-time, data-driven insights.
Digital Health Global
JUNE 20, 2023
These individuals have personally built leading technology platforms supercharging drug development globally. Their buy-in shows that our platform is differentiated and poised to unlock truly novel therapies for currently underserved patient populations through efficient, simulation-guided development. Jane Rhodes, Ph.D.,
Lloyd Price
DECEMBER 2, 2024
By embracing technological advancements, focusing on personalised medicine, and addressing the challenges of chronic wounds, the industry can improve patient outcomes, reduce costs, and enhance the overall quality of care. Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions.
Expert insights. Personalized for you.
88 
Let's personalize your content